Cumberland Pharmaceuticals reports Phase 2a ifetroban trial results

Go back to Cumberland Pharmaceuticals reports Phase 2a ifetroban trial results

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

October 23, 2026 4:05 PM EDT

Ifetroban was well tolerated in patients with systemic sclerosis

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc"). These results support the safety and tolerability of... More